FDG PET评估肿瘤反应:PERCIST更新、与EORTC标准的比较及未来发展方向线索
本文综述了FDG PET肿瘤反应评估中EORTC标准与PERCIST的底层数据,并汇总近期比较EORTC与PERCIST及二者与RECIST的临床研究。研究显示EORTC与PERCIST的反应分类非常相似,而PERCIST与RECIST之间存在显著差异;初步数据提示PERCIST与患者结局相关性更好,可能比RECIST更好地预测新抗癌疗法效果,但仍缺乏随机试验数据证实其更优的预测价值。
要点
- EORTC标准与PERCIST对肿瘤反应评估的分类结果非常相似。
- PERCIST与基于解剖的RECIST之间的反应评估存在显著差异。
- 初步数据提示PERCIST与患者结局相关性更好,可能更好地预测新抗癌疗法效果,但尚缺乏随机试验证实。
核心结论
- EORTC标准与PERCIST对FDG PET肿瘤反应评估的分类结果非常相似,而PERCIST与RECIST之间存在显著差异。
- 初步数据提示PERCIST与患者结局相关性更好,可能比RECIST更好地预测新抗癌疗法效果,若正确可能对肿瘤药物开发产生重大影响。
- 目前仍缺乏来自随机试验的数据证实PERCIST反应评估具有更优的预测价值。
研究设计与样本
- 本文为综述,描述EORTC PET标准与PERCIST两套FDG PET/CT肿瘤反应评估系统的底层数据,并汇总近期比较EORTC标准与PERCIST以及二者与RECIST的临床研究。
主要发现
- 近期临床研究显示,EORTC标准与PERCIST的反应评估导致非常相似的反应分类。
- PERCIST与RECIST的反应评估之间存在显著差异。
- 初步数据提示PERCIST反应评估与患者结局相关性更好,可能比RECIST更好地预测新抗癌疗法的效果。
局限性
- 仍缺乏来自随机试验的数据证实PERCIST反应评估具有更优的预测价值。
- 支持PERCIST预测价值更优的数据为初步数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eighteen years ago, the EORTC PET criteria standardized for the first time response assessment by FDG PET. Response assessment by FDG PET has been further developed and refined by PERCIST (PET response criteria in solid tumors). This review describes the data underlying these two systems for assessing tumor response on FDG PET/CT. It also summarizes recent clinical studies that have compared EORTC criteria and PERCIST with each other as well as with the anatomically based "response criteria in solid tumors" (RECIST). These studies have shown that response assessment by EORTC criteria and PERCIST leads to very similar response classifications. In contrast, there are significant differences between response assessment by PERCIST and RECIST. Preliminary data also suggest that response assessment by PERCIST is better correlated with patient outcome and may be a better predictor for the effectiveness of new anti-cancer therapies than RECIST. If correct, this could have a significant impact on oncologic drug development. However, confirmation of the better predictive value of response assessment by PERCIST by data from randomized trials is still lacking.
引用
- Pinker K, Riedl C, Weber WA, et al. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017. PMID: 28361188. doi:10.1007/s00259-017-3687-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。